Dr. Prebet is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
37 College St
Room 101
New Haven, CT 06511Phone+1 203-785-5531- Is this information wrong?
Education & Training
Université Claude Bernard LyonClass of 2000
Certifications & Licensure
CT State Medical License 2015 - 2024
Clinical Trials
- A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia Start of enrollment: 2016 Jul 21
- Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias Start of enrollment: 2018 Oct 29
- Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation Start of enrollment: 2020 Aug 04
- Join now to see all
Publications & Presentations
PubMed
- Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.Alberto Risueño, Wendy L See, Iryna Bluemmert, Stéphane de Botton, Andre C Schuh, Pau Montesinos, Paresh Vyas, Anita Gandhi, Maroof Hasan, Courtney D DiNardo, Amir T F...> ;Leukemia Research. 2024 Mar 27
- Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trials.Pau Montesinos, Stéphane de Botton, Yue Zhu, Carlos Enrique Vigil, Iryna Bluemmert, Xin Yu, Amir T Fathi, Eytan M Stein, Amer M Zeidan, Thomas Prebet, Courtney D DiNardo> ;Blood Advances. 2024 Mar 20
- Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.Farhad Ravandi, Hartmut Döhner, Andrew H Wei, Pau Montesinos, Michael Pfeilstöcker, Cristina Papayannidis, Yinzhi Lai, Kefeng Wang, Wendy L See, Daniel Lopes de Meneze...> ;British Journal of Haematology. 2024 Mar 1
- Join now to see all
Abstracts/Posters
- Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Rel...Thomas Prebet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloi...Thomas Prebet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Mye...Thomas Prebet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Yale Cancer Center Researchers Investigate Inducing “Synthetic Lethality” in Two Blood and Bone CancersDecember 10th, 2019
Excess Iron in MDSOctober 7th, 2016
Supportive Care Remains Backbone of Treatment in MDSMay 1st, 2015- Join now to see all
Hospital Affiliations
Yale-New Haven HospitalNew Haven, Connecticut
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
